Healios K K : Announcement of Determination of the Issue Price and Other Matters for the Issuance of New Shares through an International Offering
September 15, 2021 at 09:32 am EDT
Share
September 15, 2021
Company Name:
HEALIOS K.K.
Representative:
Hardy TS Kagimoto, Chairman & CEO
(TSE Mothers Code: 4593)
Contact:
Richard Kincaid, Executive Officer CFO
(TEL: 03-5962-9440)
Announcement of Determination of the Issue Price and Other Matters for the Issuance of New Shares
through an International Offering
HEALIOS K.K. (the "Company") hereby announces the determination of the issue price and other matters in connection with the issuance of new shares through an international offering pursuant to Regulation S under the U.S. Securities Act of 1933 (the "International Offering"), as resolved at the executive officers meeting held on September 15, 2021, as follows.
Issuance of New Shares through International Offering
Issue Price (Offer Price)
Total Amount of Issuance
Amount to be Paid
Total Amount to be Paid
Amount of Stated Capital and Additional Paid-in Capital to be Increased
¥2,175 per share
¥7,177,500,000
¥2,055.45 per share
¥6,782,985,000
Amount of Stated Capital to be Increased
¥3,391,492,500
Amount of Additional Paid-in Capital to be
¥3,391,492,500
Increased
(6)
Date of Payment
September 30,
2021
(7)
Date of Delivery
October 1,
2021
Note: The underwriter will purchase and underwrite the shares at the amount to be paid and offer the shares at the issue price (offer price).
1
1. Use of Proceeds
The total net proceeds from the International Offering is estimated to be approximately ¥6.7 billion. The Company plans to apply the total net proceeds from the International Offering as follows:
Approximately ¥2.0 billion towards the cost of further establishing commercial manufacturing capabilities in anticipation of marketing approval for HLCM051;
Approximately ¥3.0 billion towards the expenses for continued research and development of its proprietary NK cells and other pipeline assets; and
The remaining amount after deducting (1) and (2) above from the estimated net proceeds, towards general working capital for personnel expenses, etc.
Note: This press release has been prepared for the sole purpose of publicly announcing the International Offering, and not for the purpose of soliciting investment or engaging in any other similar activities within or outside Japan.
This press release is not for distribution, directly or indirectly, in or into the United States (including its territories and possessions, any State of the United States and the District of Columbia). This press release does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States. The Shares mentioned herein have not been, and will not be, registered under the United States Securities Act of 1933 (the "Securities Act").
The Shares may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the Securities Act. There will be no public offer of securities in the United States.
As the offering in connection with the issuance of new shares referred to herein will be made outside Japan and only to the non-residents of Japan, registrations or notifications under the Financial Instruments and Exchange Act of Japan (the "FIEA") will not be made, and a prospectus under the FIEA will not be prepared.
[End of Document]
Note on translation
This is an abbreviated translation of the original Japanese document and is provided for informational purpose only. If there are any discrepancies between this and the original, the original Japanese document prevails.
2
Attachments
Original document
Permalink
Disclaimer
Healios KK published this content on 15 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 15 September 2021 13:31:05 UTC.
HEALIOS K.K. is a Japan-based company mainly engaged in research and development of pharmaceutical products. The Company has compound pharmaceutical products line and induced pluripotent stem cell (iPSC) regenerative medicine product line. The compound pharmaceutical product line contains HLM0021, HLM0022 and HLM0023. The products are ophthalmological surgery adjuvants, mainly contain brilliant blue G-250 (BBG250) which help capsule temporarily safely stained to protect the inner limiting membranes and lens during surgery of vitreous and cataract. The iPSC regenerative medicine product line contains HLCR011 and HLCR012. The products are in the preclinical testing and preparation for trial in Japan, which are candidate of regenerative medicine products. The products are iPS cell derived retinal pigment epithelium (RPE) cell suspension and sheet developed in Japan, United States and Europe.